What Nrg Therapeutics say about themselves
“energizing drug discovery in neurodegenerative diseases.”
“energizing drug discovery in neurodegenerative diseases.”
Officer details are public data from the Companies House register.
People and entities with significant control, from the Companies House PSC register
Figures from 2025 accounts. Newer accounts, made up to 30 April 2026, are filed but not read yet. See them on Companies House
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Fixed Assets | £4,812 | £7,842 | £13,045 | |||
| Current Assets | £4,463,938 | £6,695,607 | £13,083,949 | £505,763 | £712,463 | £394,987 |
| Debtors | £906,169 | £1,443,284 | £9,246,145 | £148,493 | ||
| Cash | £3,557,769 | £5,252,323 | £3,837,804 | £357,270 | ||
| Creditors (< 1 year) | £2,192,833 | £1,794,832 | £765,694 | £61,116 | £162,028 | £403,454 |
| Creditors (> 1 year) | £0 | £1,603,848 | £1,010,000 | |||
| Net Current Assets | £2,271,105 | £4,900,775 | £12,318,255 | £444,647 | £550,435 | (£8,467) |
| Net Assets | £2,275,917 | £4,908,617 | £12,331,300 | (£1,159,202) | (£459,565) | (£8,467) |
| Shareholder Funds | £2,275,917 | £4,908,617 | £12,331,300 | (£1,159,202) | (£459,565) | (£8,467) |
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 7 September 2026 | Termination of appointment of a director | |||
| 7 September 2026 | Appointment of a director | |||
| 4 February 2026 | Appointment of a director | 2 | ||
| 4 February 2026 | Termination of appointment of a director | 1 | ||
| 12 December 2025 | Termination of appointment of a director | 1 |
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →